$180.77
-1.32 (-0.72%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BDX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
37 interventional · 23 observational · 23 with posted results
Held by 17 tracked-famous managers (First Eagle Investment Management, LLC, GREENHAVEN ASSOCIATES INC, HARRIS ASSOCIATES L P, AQR CAPITAL MANAGEMENT LLC, Balyasny Asset Management L.P., +12 more) · FINRA short interest 5.7 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 5 sells · government filings 180d: 2 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Personal BP - CAI StudyNCT06492746To determine the magnitude and duration of CAIOpen-label · Other | Not applicable | Recruiting | Device: HemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry Monitoring | Blood Pressure | 120 | Jan 2027 | ≤ 165 d | 2026-07-08 |
| The Continuity StudyNCT07216573Percentage of adult patients undergoing elective noncardiac surgery in the outpatient setting who experience hypotension, defined as a mean arterial pressure (MAP) < 65 mmHg, for a total duration of at least 5 minutes.Non-randomized · Open-label · Other | Not applicable | Recruiting | Device: HemoSphere Vita Monitor with VitaWave or VitaWave Plus Finger Cuff Adult, and ForeSight Large Sensors | Blood Pressure | 188 | Jan 2027 | ≤ 165 d | 2026-07-08 |
| HemoSphere Alta StudyNCT07148323observationalData Collection using HemoSphere Alta Advanced Monitoring Platform and associated devices | — | Active, not recruiting | Device: HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor | Hemodynamic Instability | 100 | Nov 2026 | ≤ 103 d | 2026-07-08 |
| UK PureWick™ At-Home Pilot StudyNCT07555548observationalRetrospective assessment of the clinical impact of problematic indwelling urinary catheters requiring intervention versus the clinical impact with the use of the PureWick™ System requiring intervention, documented during a prospective 4-week study period | — | Recruiting | Procedure: Treatment with the PureWick™ Urine Collection System External Catheter which is a non-invasive device designed to manage urinary incontinence | Urinary Incontinence | 95 | Nov 2026 | ≤ 103 d | 2026-07-13 |
| Investigational Study With the BD PosiFlush™ SafeScrub on NADsNCT06604026Device related adverse eventsRandomized · Open-label · Basic science | Not applicable | Completed | Device: BD PosiFlush™ SafeScrub, BD PosiFlush™ | CRBSI - Catheter Related Bloodstream Infection | 222 | 2026-04-30actual | — | 2026-05-01 |
| ClearSight NextGen1 StudyNCT07317648Data Collection for Development of ClearSight NextGen SystemOpen-label · Other | Not applicable | Completed | Device: ClearSight NextGen system | Blood Pressure | 35 | 2026-03-05actual | — | 2026-07-08 |
| BD SiteRite(TM) 9 Ultrasound System - Clinical StudyNCT06632509observationalPrimary Performance: To provide visualization of the target vessel in which to insert the chosen vascular access device. | — | Completed | Device: BD SiteRite(TM) 9 | BD SiteRite 9 for VAD Insertion | 149 | 2026-01-09actual | — | 2026-01-15 |
| SMART TRENDS StudyNCT05957406HPI Smart AlertNon-randomized · Open-label · Other | Not applicable | Completed | Device: Acumen HPI Smart Alerts and Smart Trends Software, The HemoSphere advanced monitoring platform with Acumen HPI software, and Acumen IQ sensor and Acumen IQ cuff | Moderate to High-risk Noncardiac Surgery | 296 | 2025-10-27actual | — | 2026-07-08 |
| Clinical Validation of BACTEC™ Plus Aerobic/F Culture Vials Compared With Equivalent ProductNCT06426121observationalconsistency rate | — | Completed | Diagnostic test: test Aerobic/F Culture Vials, control Aerobic/F Culture Vials | Sepsis | 394 | 2025-10-23actual | — | 2025-11-20 |
| BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical StudyNCT06632496observationalPrimary Performance: To provide visualization of the target vessel in which to insert the chosen vascular access device | — | Completed | Device: BD Prevue(TM) II | BD Prevue II for Peripheral Intravenous Catheter Placement | 156 | 2025-09-23actual | — | 2026-01-16 |
| Clinical Trial for Registration of HPV Nucleic Acid Genotyping Assay KitNCT04461678Verification of the accuracy of nucleic acid assayOpen-label · Diagnostic | Not applicable | Completed | Diagnostic test: HPV Genotyping Nucleic Acid Assay Kit | Cervical Cancer | 12,230 | 2024-08-26actual | — | 2025-07-02 |
| Evaluation of the BD OneFlow Acute Leukemia Panel on the BD FACSLyric Flow CytometerNCT05035615observationalComparison between expert analysts' determination of normal and abnormal specimen and final diagnosis (Sensitivity Analysis) | — | Completed | Diagnostic test: IUO Acute Leukemia Panel | Acute Leukemia | 332 | 2024-06-29actual | — | 2024-08-06 |
| Prospective Clinical Evaluation of BD NRFit™ Devices and Accessories.NCT05953363results2025-12-19observationalPrimary Performance: Rate of Participants With Successful BD Spinal NRFit™ Needle Placement in the Subarachnoid LocationStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Device: BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ Syringes | Anesthesia, Analgesia | 161 | 2024-05-28actual | — | 2025-12-19 |
| BD OneFlow CLPD Panel (BD OneFlow LST, and B-CLPD T1 to T4 Assays) on the BD FACSLyric System.NCT05557422observationalComparison between expert analysis determination for normal and abnormal specimen and final dignosis | — | Completed | Diagnostic test: BD OneFlow LST, and B-CLPD T1 to T4 Assays | Chronic Lymphoproliferative Diseases (CLPD) | 322 | 2024-05-08actual | — | 2024-09-26 |
| Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow CytometerNCT05032313observationalComparison between expert analysts' determination of normal and abnormal specimen and final diagnosis | — | Completed | Diagnostic test: IUO CLPD Limited Panel | Chronic Lymphoproliferative Diseases (CLPD) | 371 | 2023-12-29actual | — | 2024-02-28 |
| Study of BD Pre-filled Flush Syringes in ChinaNCT05763147results2024-07-30the Overall Performance for Flushing and / or Locking the Catheters.Randomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Not applicable | Completed | Device: Intravenous Access Device Flushing | Effectiveness and Safety of Pre-filled Flush Syringe | 378 | 2023-12-26actual | — | 2024-07-30 |
| Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow CytometerNCT05032339observationalComparison between expert analysts' determination of normal and abnormal specimen and final diagnosis | — | Completed | Diagnostic test: IUO Plasma Cell Disorders Panel | Plasma Cell Disorder | 208 | 2023-10-25actual | — | 2023-10-30 |
| A Post-Market Clinical Follow Up Study to Evaluate BD PureHub™ Disinfecting Cap Use on Needle-Free ConnectorsNCT05130762results2025-01-27Attachment & Removal Success Rate of the BD PureHub Disinfecting Caps to a Needle-free ConnectorOpen-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: BD PureHub™ Disinfecting Cap Placements: Attachments/removals | Catheter Related Complication, Vascular Access Site Management, Disinfecting Cap | 157 | 2023-05-22actual | — | 2025-01-27 |
| BD Veritor™ At-Home and BD Veritor™ ProfessionalNCT05352581observationalDiagnostic accuracy of the BD Veritor At-Home Assay | — | Completed | Diagnostic test: BD Veritor At-Home, BD Veritor Professional | Upper Respiratory Infection | 1,146 | 2023-03-09actual | — | 2023-06-07 |
| Investigational On-body Injector Clinical StudyNCT05553418Device Performance - Dose delivery efficiencyRandomized · Open-label · Other | Not applicable | Completed | Device: In-clinic wear first, Home wear first | Healthy Volunteers | 70 | 2023-02-08actual | — | 2025-02-03 |
| BD MiniDraw™ Capillary System Clinical Equivalence StudyNCT05186311results2023-09-21Chemistry Analytes [Albumin (ALB) and Total Protein (TP)] in Serum Measured Using the Silica Clot Activator for Serum SamplesOpen-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: Capillary Blood Collection System | Healthy, Disease, Chronic, Acute Disease, Sample Collection | 262 | 2022-10-24actual | — | 2023-11-03 |
| Prospective Clinical Evaluation of BD Spinal NeedlesNCT05214560results2024-08-19observationalPrimary Safety: Incidence of Post-dural Puncture Headache (PDPH).Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Device: Spinal needle | Analgesia, Anesthesia | 160 | 2022-07-22actual | — | 2024-08-19 |
| A Clinical Trial Evaluating the Effectiveness and Safety of the PowerMe Midline Catheter in the Chinese PopulationNCT04719377Acceptance of the overall performance of the IV catheter systemRandomized · Open-label · Treatment | Not applicable | Completed | Device: catheter placement | Catheterization | 256 | 2022-01-30actual | — | 2022-09-23 |
| Prospective Observational Study of the Power PICC Family of Devices and AccessoriesNCT04263649results2024-08-19observationalPrimary Safety: Incidence of Symptomatic Venous Thrombosis in Patients With a Device From the BD PowerPICC Family Used for Both Short- and Long-term Venous Access.Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Device: Peripherally Inserted Central Catheter | Peripherally Inserted Central Catheter | 450 | 2022-01-05actual | — | 2024-08-19 |
| Capturing Infectious COVID-19 Asymptomatic Cases in SingaporeNCT04812327observationalAssess the performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 compared viral culture, over multiple collection time points | — | Withdrawnsponsor's stated reason: Study was cancelled prior enrollment due to business decision. | Diagnostic test: BD Veritor Plus System for Rapid Detection of SARS CoV-2, rt-PCR, viral culture | Covid19, SARS CoV-2 | 0 | Sep 2021 | — | 2021-08-11 |
| A 7 Day Adhesive Device Wear Study to Evaluate BD StatLock™ DevicesNCT04845906observationalPercent lift of the StatLock™ Catheter Stabilization Device Pad at Day 7 | — | Completed | Device: StatLock™ Catheter Stabilization Device and the StatLock™ stabilization device accessory (Foam Strip) | Peripheral Intravenous Catheter Stabilization | 120 | 2021-08-23actual | — | 2021-09-08 |
| Prospective Healthy Volunteer Study of the Securis™ Stabilization DeviceNCT04841330observationalRate of Securis™ Stabilization Device Securement Failure During Simulated Use | — | Completed | Device: Securis™ Stabilization Device | Peripheral Intavenous Catheter Stabilization | 104 | 2021-07-20actual | — | 2021-09-08 |
| The Role of Proper Insulin Injection Technique in the Treatment of Diabetes MellitusNCT04120974results2024-02-22Change in Glycemic ControlOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Behavioral: Optimal insulin injection | Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Lipohypertrophy | 90 | 2021-04-26actual | — | 2024-02-22 |
| Impact of PIVC Length and Gauge on Catheter Indwell TimeNCT04344314results2024-05-16Patent Indwell Time Between PIVCs of Different Length and Gauge.Randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Peripheral Intravenous Catheter | Indication for Peripheral Intravenous Catheterisation | 40 | 2021-03-12actual | — | 2024-05-16 |
| Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 DiabetesNCT04090242results2021-07-08Change in Attitude Toward Diabetes - Diabetes Empowerment Scale (DES) From Baseline to End of StudyRandomized · Open-label · Supportive careStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Enrollment halted prematurely due to the Covid-19 pandemic | Device: BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle | Diabetes Mellitus, Type 2 | 58 | 2020-06-12actual | — | 2021-07-08 |
| Evaluation of the Antimicrobial Effectiveness of CHG/IPANCT04035161results2021-08-17Antimicrobial log10 Reductions From Baseline for Investigational Product and Reference Standard at 30 Seconds and 6 Hours Post-product ApplicationRandomized · Single-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Combination product: Investigational Product, Active Comparator · Other: Reference Standard, Negative Control | Microbial Colonization | 1,935 | 2019-12-24actual | — | 2021-08-17 |
| Efficiency, and Emergency Department Nurse Preference Between 2 Methods of Visualization: A Pilot StudyNCT04811430observationalInsertion Success | — | Completed | Device: Randomized Traditional, Cue(TM) Needle Tracking Technology | Catheter Related Complication | 49 | 2019-10-14actual | — | 2021-03-23 |
| An Audit of the Impact of Tailored Information Delivered Via a Digital Learning PlatformNCT04007003Change in Insulin UseOpen-label · Supportive care | Not applicable | Terminatedsponsor's stated reason: Sponsor decision | Behavioral: training in optimal insulin injection technique | Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1 | 170 | 2019-08-10actual | — | 2019-12-03 |
| Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen NeedleNCT03878745results2020-05-19BD Nano™ PRO Pen Needle Compared to Terumo Nanopass® (Injection Pain)Non-randomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Terumo Nanopass® 34G pen needle, BD Nano™ PRO 32G pen needle | Diabetes | 55 | 2019-06-14actual | — | 2020-05-19 |
| Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs Three Commercially Available Pen NeedlesNCT03878758results2020-03-09Injection Site Pain for BD Nano PRO Needle Compared to Each of Three (3) Commercially Available ComparatorsRandomized · Single-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: BD Nano™ PRO, 33G Artsana Insupen Extr3me, 34G Artsana Insupen Extr3me, Simple Diagnostics Comfort EZ™ | Diabetes | 158 | 2019-04-30actual | — | 2020-03-09 |
| Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical SpecimensNCT02267876observationalCumulative risk of Cervical Intraepithelial Neoplasia 2 and 3 (CIN2 and CIN3) over three years in Human Papillomavirus (HPV) Positive Patients. | — | Completed | Device: BD HPV Assay on Viper LT · Procedure: Colposcopy | Cervical Neoplasms, Human Papillomavirus | 6,730 | 2018-12-12actual | — | 2021-02-08 |
| Evaluating the User Performance and Experience of Nucleus Pen vs. Commercially Available Pen NeedleNCT03267264results2019-07-16Overall User Preference -Combined GroupsRandomized · Open-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: BD Nano™ vs Nucleus, NovoFine® vs Nucleus, NovoTwist®/NovoFine® Plus vs Nucleus, Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus | Diabetes | 248 | 2018-04-24actual | — | 2019-07-16 |
| The PSIQS Study - User Experience With Pro-SetNCT03242005Compare Pro-set® vs. Quick-set® for non-inferiority for set insertion failures (set removal) due to either occlusion alerts or hyperglycemiaRandomized · Open-label · Other | Not applicable | Withdrawnsponsor's stated reason: Sponsor decision to not proceed with study - no subjects enrolled | Device: MiniMed® Pro-set®, MiniMed® Quick-set® | Diabetes Mellitus, Type 1 | 0 | Dec 2017 | — | 2017-09-14 |
| Effectiveness of an Antimicrobial Agent for Preoperative Skin PreparationNCT03224299results2021-04-23Antimicrobial Activity of the Investigational Products Compared to Control.Randomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: OCT - clear, OCT- tinted · Other: ChloraPrep, Saline | Preoperative Skin Preparation | 131 | 2017-08-24actual | — | 2021-04-23 |
| Evaluation of the Antimicrobial Effectiveness of an Antimicrobial ClothNCT03229759results2021-04-23Bacterial Count at 10 Minutes Post ApplicationRandomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Octenidine Dihydrocloride in aqueous solution · Other: Vehicle Control, Saline Control | Preoperative Skin Preparation | 99 | 2017-08-04actual | — | 2021-04-23 |
| Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS SamplesNCT03020121SensitivityOpen-label · Diagnostic | Not applicable | Terminatedsponsor's stated reason: Lower than anticipated rate of subject enrollment | Procedure: Colposcopy/biopsy | Uterine Cervical Neoplasm | 28 | May 2017actual | — | 2018-01-31 |
| Treating Diabetic Lipohypertrophy With Intensive Education Versus Standard CareNCT02271594results2021-06-09HbA1cRandomized · Open-label · Treatment | Not applicable | Terminated | Behavioral: Intensive Training on Best Insulin Injection Technique, Standard education on injection technique | Insulin Injections and Lipohypertrophy | 31 | Aug 2016actual | — | 2021-06-09 |
| Clinical Evaluation of the BD Onclarity™ HPV Assay on the BD Viper™ LT System With Cervical SpecimensNCT01944722results2018-04-18Sensitivity of the BD Onclarity™ HPV Assay for the Detection Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN)2 or GreaterOpen-label · Diagnostic | Not applicable | Completed | Device: BD Onclarity™ HPV assay on BD Viper™ LT · Procedure: Colposcopy | Uterine Cervical Neoplasms | 33,858 | Mar 2016actual | — | 2018-06-12 |
| BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims StudyNCT02662842observationalComparative Infusion Set Insertion Pain | — | Completed | Device: FlowSmart Infusion Set, Current Infusion Set | Type 1 Diabetes Mellitus | 75 | Feb 2016actual | — | 2017-04-13 |
| Accuracy Evaluation of the BD FACS Presto SystemNCT02396355observationalMethod bias between BD FACSPresto System vs. Predicate in venous blood (AbsCD4 and %CD4) | — | Completed | Device: Investigational BD FACSPresto System, BD FACSCalibur flow cytometer, Sysmex hematology analyzer KX-21 | Acquired Immunodeficiency Syndrome | 583 | May 2015actual | — | 2017-02-09 |
| Monitoring the Infusion Pressure in Insulin Infusion Sets in Healthy AdultsNCT02382536observationalIn-line fluid pressure | — | Completed | Device: BD Scarlett Infusion set, Medtronic QuickSet Infusion Set | Diabetes | 60 | Aug 2014actual | — | 2017-02-09 |
| European Clinical Evaluation of the BD HPV Assay on the BD Viper LT SystemNCT01671462observationalSensitivity of the BD HPV Assay with 95% confidence intervals for detecting cervical disease as defined by Cervical Intraepithelial Neoplasia (CIN2) or higher. | — | Completed | Device: BD HPV assay on Viper LT | Uterine Cervical Neoplasms | 1,365 | Nov 2013actual | — | 2014-02-20 |
| Study of Effectiveness of Smaller Gauge Fenestrated Catheters for Use in IV Contrast Enhanced CT ScansNCT01772550results2014-03-26Acceptable Image QualityRandomized · Open-label · Diagnostic | Not applicable | Completed | Device: 20GA BD Nexiva Diffusics, 18GA Conventional Catheter | Contrast Enhanced Computed Tomography | 238 | Feb 2013actual | — | 2014-05-02 |
| Clinical Evaluation of BD NEXT Pen NeedleNCT01852136observationalOverall Pen Needle Preference | — | Completed | Device: BD NEXT 31G x 5 mm pen needle, BD NEXT 31G x 8mm pen needle, BD NEXT 32G x 4mm pen needle | Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1 | 217 | Dec 2012actual | — | 2017-02-09 |
| Three-day, In-clinic Evaluation of the BD 2nd Generation Continuous Glucose Sensor Device in Type 1 DiabeticsNCT01645696Blood GlucoseNon-randomized · Open-label · Device feasibility | Not applicable | Completed | Device: BD CGM with Outer Layer, BD CGM without Outer Layer, Medtronic iPro2 Professional CGM | Diabetes | 30 | Sep 2012actual | — | 2021-12-29 |
| Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen NeedlesNCT01231984results2014-06-27Glycemic Control as Measured by HbA1c (4 mm vs. 8 mm)Randomized · Open-label · Other | Not applicable | Completed | Device: 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 293 | May 2012actual | — | 2024-09-19 |
| Multi-day (3) In-patient Evaluation of Intradermal Versus Subcutaneous Basal and Bolus Insulin InfusionNCT01557907Insulin levelsRandomized · Open-label · Treatment | Phase 1/2 | Completed | Device: Subcutaneous delivery via Medtronic Quick-Set, Intradermal delivery via the BD Research Catheter Set | Diabetes | 23 | May 2012actual | — | 2012-07-26 |
| Intended Use Study of the BD SurePath Plus™ PapNCT01234480results2021-05-05Sensitivity, Specificity, PPV, and NPV of BD SurePath Plus Pap Test for the Determination of Cervical Disease as Defined by CIN2 or HigherNon-randomized · Open-label · Diagnostic | — | Terminatedsponsor's stated reason: Decided not to pursue commercialization of the product | Device: BD SurePath Plus Pap test, BD SurePath Pap test, HPV DNA test · Procedure: colposcopy with biopsy/ECC | Uterine Cervical Neoplasms, Uterine Cervical Cancer, Neoplasms, Squamous Cell, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neoplasms, Papilloma | 5,859 | Mar 2012actual | — | 2023-05-16 |
| Evaluation of a 4mmx32G Pen Needle for Injection of Basal Insulin Doses Above 40 UnitsNCT01334606results2013-09-02Glycemic Control as Measured by Percent (%) Absolute Change in FructosamineRandomized · Open-label · Other | Not applicable | Terminatedsponsor's stated reason: This study was terminated due to unanticipated recruitment difficulties. | Device: 4 mm x 32G pen needle (Nano), 8mm x 31G pen needle (Short) | Diabetes Mellitus, Type 2 | 21 | Jun 2011actual | — | 2022-03-10 |
| Study on the Effects on Blood Glucose Following Intradermal and Subcutaneous Dosing of Insulin in Diabetic PatientsNCT01120444Blood GlucoseRandomized · Open-label · Basic science | Phase 1/2 | Completed | Device: BD Research Catheter with 34G x 1.5 mm needle, Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set | Diabetes | 20 | Oct 2010actual | — | 2011-04-18 |
| Pharmacokinetics/Dynamics of Basal (Continuous) Insulin Infusion Administered Either Intradermally or SubcutaneouslyNCT01061216Insulin measurements will be used to compute PK model parameters: absorption rate(s) and elimination rate using an appropriate transport model.Randomized · Open-label · Basic science | Phase 1/2 | Completed | Device: Intradermal insulin delivery: BD Research Catheter Set, Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 20 | Mar 2010actual | — | 2010-03-10 |
| Comparison of Glycemic Control Among Diabetics Using Three Different Pen NeedlesNCT00928057results2010-10-20Percent (%) Absolute Change in FructosamineRandomized · Open-label | Not applicable | Completed | Device: 4mm x 32G pen needle, 8mm x 31G pen needle, 5mm x 31G pen needle | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 173 | Nov 2009actual | — | 2010-10-20 |
| A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous SpacesNCT01093833Blood GlucoseOpen-label · Basic science | Phase 1 | Completed | Device: BD Continuous glucose monitor (BD CGM), YSI Glucose Analyzer, Medtronic Guardian CGM | Diabetes | 40 | Apr 2009actual | — | 2016-05-06 |
| Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood GlucoseNCT00741390results2010-03-10Blood Sample of Sufficient Volume to Yield a Valid Meter ReadingRandomized · Single-masked | Not applicable | Completed | Device: BD/33G, OTM / 33G, OTU/28G, ACC/28G, OTM/28G | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 250 | Sep 2008actual | — | 2010-03-10 |
| Feasibility Study of the Effect of Intra-Dermal Insulin Injection on Blood Glucose Levels After EatingNCT00553488Area Under Curve (AUC) of the blood glucose (BG) profile after the meal, with and without baseline correction.Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Regular insulin (Humulin), Insulin lispro (Humalog) | Diabetes Mellitus, Type 1 | 30 | Dec 2007actual | — | 2008-08-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19